Related Experiment Video
Updated: Jul 19, 2026
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Novel robust hepatitis C virus mouse efficacy model
Qing Zhu1, Yoko Oei, Dirk B Mendel
1Department of Pharmacology, Novartis Vaccines and Diagnostics, Chiron Corportion, Emeryville, CA 94608. Qing_zhu@chiron.com
Abstract:
The lack of a robust small-animal model for hepatitis C virus (HCV) has hindered the discovery and development of novel drug treatments for HCV infections. We developed a reproducible and easily accessible xenograft mouse efficacy model in which HCV RNA replication is accurately monitored in vivo by real-time, noninvasive whole-body imaging of gamma-irradiated SCID mice implanted with a mouse-adapted luciferase replicon-containing Huh-7 cell line (T7-11). The model was validated by demonstrating that both a small-molecule NS3/4A protease inhibitor (BILN 2061) and human alpha interferon (IFN-alpha) decreased HCV RNA replication and that treatment withdrawal resulted in a rebound in replication, which paralleled clinical outcomes in humans. We further showed that protease inhibitor and IFN-alpha combination therapy was more effective in reducing HCV RNA replication than treatment with each compound alone and supports testing in humans. This robust mouse efficacy model provides a powerful tool for rapid evaluation of potential anti-HCV compounds in vivo as part of aggressive drug discovery efforts.
Insights
Researchers developed a new mouse model to test hepatitis C virus (HCV) drugs. This model accurately tracks viral RNA replication, aiding in the discovery of effective antiviral therapies.
Area of Science:
- Hepatology
- Virology
- Drug Discovery
Background:
- Hepatitis C virus (HCV) drug development is hampered by the absence of effective small-animal models.
- Accurate in vivo monitoring of viral replication is crucial for evaluating antiviral efficacy.
Purpose of the Study:
- To develop and validate a reproducible xenograft mouse model for evaluating anti-HCV therapies.
- To enable noninvasive, real-time monitoring of HCV RNA replication in vivo.
Main Methods:
- Development of a xenograft mouse model using gamma-irradiated SCID mice engrafted with a luciferase-expressing HCV replicon cell line (T7-11).
- In vivo monitoring of HCV RNA replication via noninvasive, whole-body imaging.
- Validation using a protease inhibitor (BILN 2061) and interferon-alpha (IFN-alpha), assessing replication dynamics upon treatment and withdrawal.
Main Results:
- The T7-11 xenograft model accurately reflects HCV RNA replication in vivo.
- Both BILN 2061 and IFN-alpha demonstrated significant reduction in HCV RNA replication.
- Treatment withdrawal led to a rebound in viral replication, mirroring human clinical outcomes.
- Combination therapy of protease inhibitor and IFN-alpha showed superior efficacy compared to monotherapy.
Conclusions:
- A robust and accessible xenograft mouse model for HCV has been established.
- This model facilitates rapid in vivo evaluation of potential anti-HCV compounds.
- The findings support the use of this model in drug discovery efforts for hepatitis C.
